

December 26, 2014

To,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block
Bandra - Kurla Complex, Bandra (E)
Mumbai - 400 051
(NSE Scrip Code: TORNTPHARM)

Dear Sir / Madam,

Sub: CLARIFICATION on news item captioned "Torrent Pharma in pact with Reliance Life to sell biosimilars" appearing in Business Line dated December 26, 2014

Ref: Your Email dated December 26, 2014

This is with reference to your above email on the subject.

In this regard we would like to inform that the Company, in the ordinary course of business, do take on license various products and also give license of its various products to third parties. In line with this, the Company has, during last one month, entered into licensing agreements with Reliance Life Sciences for marketing of three biosimilars in Indian market. These products are at various stages of developments / Regulatory approvals.

Considering Company's size of operations, in our view, these transactions are not material in nature and do not have any significant impact on the performance of the Company and hence does not qualify for intimation to Stock Exchanges under clause 36 of the Listing Agreement.

As a responsible listed organization, we do inform the exchanges of all information which require to be disclosed, on timely basis in terms of the Listing Agreement and will keep the exchange informed in future as well.

Thanks & Regards,

For TORRENT PHARMACEUTICALS LIMITED



MAHESH AGRAWAL
VP (LEGAL) & COMPANY SECRETARY

TORRENT PHARMACEUTICALS LIMITED

CIN : L24230GJ1972PLC002126

Reg. Office : Torrent House, Off Ashram Road, Ahmedabad - 380 009, India. Phone: +91 79 26585090 www.torrentpharma.com